Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vaxxinity Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, WANG, CHANG YU, who is responsible for 1 pending office action. The concentration of the entire pending portfolio under 1 distinct examiner suggests a singular point of contact for current prosecution efforts.
The portfolio is active within 1 distinct art unit, indicating that the technical scope of the pending application is highly focused. Because WANG, CHANG YU manages the only 1 pending action, the success of the current portfolio rests entirely on the resolution of this examiner's requirements. This lack of examiner diversity means that the company cannot leverage different perspectives within the Biotechnology & Pharmaceuticals field.
With 1 distinct art unit and 1 distinct examiner involved, the prosecution strategy is streamlined but also carries higher risk. The fact that 1 pending office action is the only active matter means that any delay or rejection from WANG, CHANG YU will impact the entire pending portfolio. Practitioners should focus on meeting the specific technical standards of this 1 distinct art unit to clear the current 1 pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688196 | METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES | WANG, CHANG YU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688196 | METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES | WANG, CHANG YU | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688196 | METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES | WANG, CHANG YU | 1675 | §102§103§112 | Non-Final OA | — | Pending | Feb 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVaxxinity Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chang Yu Wang has the most, with 1 of Vaxxinity Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
